Share

EORTC embarked on a membership renewal programme

In 2020, EORTC embarked on an ambitious membership renewal programme, in order to comply with GDPR regulation and to ensure that all information of its members are up to date. Following this renewal programme, EORTC can confirm over 2800 direct members coming from 730 institutions. The network comprises of members coming from 48 countries around the world, with the top ten from Europe.

Countries of EORTC members - graph

EORTC is a truly multidisciplinary organisation of which 15% are organ specialists. Its membership spans over 30 different disciplines conducting clinical research.

EORTC members profile - graph

“One of the uniqueness of EORTC is that we conduct trials across multiple tumours and the members are stratified across groups related to their tumour of interest. We are able to attract leading clinical researchers across the globe, conducting practice changing trials,” said Denis Lacombe, EORTC Director General. “As EORTC approaches its 60th anniversary next year, we remain fully committed to all cancer patients, our members, partners and supporters, ensuring the organisation stays true to its mission and paves the way to innovation in cancer care.”

Back to news list

Related News

  • EORTC and Immunocore announce enrolment of first patient onto the only active Phase 3 adjuvant trial in uveal melanoma

  • Minister F. Vandenbroucke visits EORTC Headquarters to strengthen collaborative efforts in clinical cancer research

  • IMMUcan has completed patient enrolment

  • EORTC SPRINT clinical cancer study receives support from Rising Tide Foundation to reduce the burden for patients

  • Pink October at EORTC: Over 60 years of impactful breast cancer research

  • Spotlight on ENA 2024 News

  • Do regulations and policies undermine the social value of independent academic research?

  • EORTC Quality of Life Group’s participation to ISOQOL 2024

  • New Insights into Glioblastoma Treatment for Older Adults Patients

  • TOPGEAR trial results show no significant benefit of preoperative chemoradiotherapy on long term survival